GHK-Cu (Copper Peptide): What the Skin & Collagen Research Actually Shows

Updated August 1, 2026 · Universe Peptide Research Desk

GHK-Cu is a naturally occurring copper-binding tripeptide — glycyl-L-histidyl-L-lysine (GHK) coordinated to a copper(II) ion — first isolated from human plasma in the 1970s by biochemist Loren Pickart. It has since become one of the most extensively studied molecules in skin-regeneration and copper-biology research, with a literature trail spanning more than 35 years. This article summarizes what fibroblast, animal, and gene-expression studies report, and — just as importantly — where the human clinical evidence remains thin.

A copper-delivery peptide, not a drug

GHK-Cu's core biochemical role is to bind and transport copper(II) to enzymes and cells that depend on it. Copper is a required cofactor for several enzymes involved in building and maintaining the extracellular matrix, including lysyl oxidase, the enzyme responsible for cross-linking collagen and elastin fibers. Researchers have proposed that GHK-Cu's activity in skin and connective-tissue models is largely a function of this copper-delivery role rather than a conventional receptor-ligand mechanism.

The original fibroblast studies: collagen synthesis

One of the foundational experiments in this field is Maquart and colleagues' 1988 study in FEBS Letters, which reported that the GHK-copper complex stimulated collagen synthesis in cultured skin fibroblasts, with an effect beginning at concentrations between 10⁻¹² and 10⁻¹¹ M and peaking around 10⁻⁹ M — independent of any change in cell number. That concentration-dependence in a cell-culture model is a classic reference point cited throughout the later GHK-Cu literature.

Large-scale gene-expression findings

Beyond single-pathway effects, Pickart and Margolina's 2018 review in the International Journal of Molecular Sciences analyzed GHK's signature against the Broad Institute's Connectivity Map (CMap) — a large public dataset mapping how compounds shift gene-expression profiles across cultured human cells. The review reports that GHK's expression signature overlapped with a very large share of the genes surveyed in that dataset, with patterns consistent with upregulation of tissue-repair and antioxidant-related genes and downregulation of genes linked to inflammation and tissue breakdown. This is a computational, correlational finding from a public gene-expression database — it describes an association across cultured-cell data, not a demonstrated clinical outcome in living organisms.

What has been studied, and in what kind of model

Reading across the GHK-Cu literature, the reported findings cluster into a few recurring categories. Each of the following comes from in-vitro (cultured cell) or animal-model research — none should be read as an established human clinical outcome:

• Collagen and elastin synthesis. Reported stimulation of collagen types I and III and glycosaminoglycan production in dermal fibroblast cultures, alongside proposed support of elastin fiber formation via copper-dependent lysyl oxidase activity.
• Extracellular-matrix remodeling. Studies describing modulation of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in skin models — the balance of enzymes that build up and break down the dermal matrix.
• Wound-healing models. Reports of accelerated wound closure and altered inflammatory-cytokine signaling in animal and cell-based wound assays.
• Gene-expression modulation. Broad shifts across repair, antioxidant and DNA-repair-associated genes identified through Connectivity Map analyses, as above.
• Recent fibroblast and ex-vivo skin work. A 2023 study examined GHK-Cu in combination with hyaluronic acid and reported upregulation of collagen IV in fibroblast and ex-vivo skin-tissue models.

Where the human evidence is weak or absent

This is the section any responsible summary of GHK-Cu needs to state plainly. The in-vitro and animal-model evidence for GHK-Cu is substantial and decades deep, spanning fibroblast collagen-synthesis assays, matrix-remodeling studies, wound-healing models in animals, and large-scale gene-expression analyses. Much of the copper peptide's public reputation, however, rests on cosmetic-industry marketing built loosely on top of that preclinical base rather than on large, independent, controlled human trials.

Rigorous, adequately powered, independently replicated human clinical trials of injectable or systemic GHK-Cu are essentially lacking. Topical cosmetic formulations are a separate regulatory category from the research-grade lyophilized peptide discussed here, and cosmetic-product testing does not establish safety or efficacy for laboratory compounds intended for in-vitro use. Extrapolating fibroblast-culture or animal-model findings directly to expected human outcomes is the exact overreach this field is prone to, and this article does not make that leap.

Sources

1. Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺. FEBS Letters, 1988. PMID 3169264. pubmed.ncbi.nlm.nih.gov
2. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International, 2015. PMID 26236730. pubmed.ncbi.nlm.nih.gov
3. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences, 2018;19(7):1987. PMID 29986520. doi:10.3390/ijms19071987 pubmed.ncbi.nlm.nih.gov
4. Synergy of GHK-Cu and hyaluronic acid on collagen IV upregulation via fibroblast and ex-vivo skin tests. PubMed, 2023. PMID 37062921. pubmed.ncbi.nlm.nih.gov

This article is provided for educational and informational purposes to the research community. Universe Peptide products, including GHK-Cu, are sold for laboratory research only, are not for human or animal consumption, and are not approved by the FDA for any therapeutic or cosmetic use. Buyers must be 21+.